Donnelly Richard G 4/A
4/A · AspenBio Pharma, Inc. · Filed Jan 17, 2006
Insider Transaction Report
Form 4/AAmended
Donnelly Richard G
DirectorPresident & CEO
Transactions
- Award
Options (Right to Buy)
2005-12-23+100,000→ 100,000 totalExercise: $0.96From: 2006-07-01Exp: 2015-12-23→ Common Stock (100,000 underlying) - Award
Common Stock
2005-12-23+75,000→ 150,823 total - Purchase
Common Stock
2005-12-28$0.95/sh+5,000$4,750→ 155,823 total
Holdings
- 500,000
Options (Right to Buy)
Exercise: $0.60From: 2005-02-01Exp: 2015-02-01→ Common Stock (500,000 underlying) - 28,571
Warrants (Right to Buy)
Exercise: $1.35From: 2005-05-06Exp: 2010-05-06→ Common Stock (28,571 underlying)
Footnotes (5)
- [F1]Pursuant to Board minutes dated December 23, 2005, the Company's Board of Directors awarded Mr. Donnelly 75,000 restricted shares of the Company's common stock. This stock award is exempt from Section 16(b) pursuant to Rule 16b-3d.
- [F2]Mr. Donnelly purchased 5,000 shares of the Company's common stock on the open market for $0.95 per share. This transaction was reported on a Form 4 filed on January 9, 2006.
- [F3]Options vest over three years, at the rate of 33.3% at the end of year one, 66.7% at the end of year two, and 100% at the end of year three.
- [F4]Units purchased at a unit price of $0.875, with each unit consisting of one warrant and one share of common stock.
- [F5]Pursuant to Board minutes dated December 23, 2005, the Company's Board of Directors granted Mr. Donnelly stock options to purchase 100,000 shares of the Company's common stock at $0.96 per share. The stock options vest on July 1, 2006, assuming that a cumulative minimum of $500,000 of sales of the new equine LH product is achieved by June 30, 2006. If such sales threshold is not achieved by June 30, 2006, the options shall lapse and expire. This stock option grant is exempt from Section 16(b) pursuant to Rule 16b-3d.